Diagnostic Accuracy of Magnetic Resonance Spectroscopy in Diagnosing Carcinoma Prostate

Abstract

Background: Magnetic resonance spectroscopy (1H-MRS) produces a non-invasive analysis of the metabolism of the tissue, determining the relative concentrations of their metabolites and the interactions produced between them, which may be used in tumor diagnosis and showed good diagnostic accuracy for prostate cancer detection. Objective: To determine the diagnostic accuracy of Magnetic Resonance Spectroscopy (MRS) in diagnosing prostate cancer. Methodology: This was a cross sectional study, conducted at department of Radiology, Bahawal Vitoria Hospital, Bahawalpur, from July 2019 to June 2020. A total of 206 male patients with clinical suspicion of carcinoma prostate, 50-80 years of age will be included. Patients with already diagnosed carcinoma prostate, prostatic abscess, acute or chronic prostatitis were excluded. Each patient has undergone MRS examination. Each MRS was interpreted by one consultant radiologist and was looked for choline + creatine/citrate ratio for carcinoma prostate. Findings of MRS and histopathology were correlated. Data were analyzed by using SPSS 20. Results: In 120 MRS-positive patients, 108 were True Positive and 12 were False Positive. Among, 86 MRS negative patients, 16 were False Negative whereas 70 were True Negative. Overall sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of magnetic resonance spectroscopy (MRS) in diagnosing carcinoma prostate was 87.10%, 85.37%, 90.0% 81.40%, and 86.41% respectively. Conclusion: This study concluded that Magnetic Resonance Spectroscopy is the non-invasive modality of choice with high diagnostic accuracy in detecting prostate cancer.